We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+1.1%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$262M
AUM Growth
-$74M
(-22%)
Cap. Flow
-$64.8M
Cap. Flow
% of AUM
-24.76%
Top 10 Holdings %
Top 10 Hldgs %
58.8%
Holding
64
New
10
Increased
31
Reduced
6
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$15.4M |
| 2 |
Disc Medicine
IRON
|
+$9.92M |
| 3 |
Sanofi
SNY
|
+$9.58M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$7.78M |
| 5 |
Maximus
MMS
|
+$5.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$35.6M |
| 2 |
Zimmer Biomet
ZBH
|
+$21.2M |
| 3 |
Labcorp
LH
|
+$19.5M |
| 4 |
Teleflex
TFX
|
+$14.9M |
| 5 |
Embecta
EMBC
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.46% |
| 2 | Industrials | 14.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Rocket Pharmaceuticals Warrant
RCKTW
$342K
| $13.6K | 0.01% |
400,000
| – | – |
|
|
ATYR
52
PUT
aTyr Pharma
ATYR
$48.2M
| $5.58K | ﹤0.01% |
+1,100
| New | +$4.33K |
|
|
AKRO
53
DELISTED
Akero Therapeutics
AKRO
| – | – |
-85,000
| Closed | -$3.44M |
|
|
ETNB
54
DELISTED
89bio
ETNB
| – | – |
-500,000
| Closed | -$3.63M |
|
55
Haemonetics
HAE
$3.94B
| – | – |
-133,966
| Closed | -$8.51M |
|
|
56
Icon
ICLR
$12.2B
| – | – |
-203,311
| Closed | -$35.6M |
|
57
Ironwood Pharmaceuticals
IRWD
$728M
| – | – |
-1,017,616
| Closed | -$1.5M |
|
|
58
Labcorp
LH
$24.9B
| – | – |
-83,873
| Closed | -$19.5M |
|
59
Praxis Precision Medicines
PRAX
$8.52B
| – | – |
-112,500
| Closed | -$4.26M |
|
|
SLNO
60
PUT
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-78,300
| Closed | -$5.59M |
|
61
Protara Therapeutics
TARA
$223M
| – | – |
-1,514,300
| Closed | -$6.45M |
|
|
62
Teleflex
TFX
$6.18B
| – | – |
-107,780
| Closed | -$14.9M |
|
|
VXRT
63
DELISTED
Vaxart
VXRT
| – | – |
-5,583,448
| Closed | -$2.27M |
|
|
64
Zimmer Biomet
ZBH
$18.8B
| – | – |
-187,685
| Closed | -$21.2M |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Sio Capital Management held 64 positions worth $262M, down 22% from $336M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Sio Capital Management withdrew a net $64.8M in Q2 2025, closing 12 positions and reducing 6 holdings. Its most notable exit was Icon, an estimated $35.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 89% a quarter earlier, followed by Industrials.
Against the trend, Sio Capital Management opened a new position in Centene worth $14.2M.
- Sio Capital Management's largest Q2 2025 buy was Centene: 262,500 shares worth $14.2M.
- Sio Capital Management added most to Disc Medicine in Q2 2025, an estimated $9.92M increase.
- Sio Capital Management's biggest Q2 2025 reduction was Embecta, cutting an estimated $12.1M.
- Sio Capital Management fully exited Icon in Q2 2025, selling an estimated $35.6M.
- Sio Capital Management's ten largest holdings make up 59% of its $262M portfolio in Q2 2025.
- Sio Capital Management opened 10 new positions and closed 12 in Q2 2025.
- Sio Capital Management's portfolio value fell 22% quarter-over-quarter to $262M.
Based on Sio Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.